中文 / CN
Deutsch / DE
日本語 / JP
한글 / KR
Contact Us
Menu
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Protein Sciences

Uniting Drug Development Expertise with Antibody & Protein Production Services

Antibody Drug Development

Antibody drugs have ushered in a new era of targeted treatments for many human diseases, including cancer, autoimmune disorders, and infectious diseases. Scientists have harnessed the unique specificities of diseases to design potent antibody drugs that target cellular or molecular pathways with unparalleled precision. Today, several FDA-approved monoclonal antibodies have become standard treatments for various ailments, leading to significant improvements in patient care and outcomes.

 

Among the advancements in antibody drugs, bispecific antibodies (bsAbs) are gaining increasing popularity, alongside AI-driven antibody drug development. Furthermore, the shift towards personalized medicine is fueling the development of patient-specific antibody drugs. Given these evolving trends and the challenges they present, our dedicated team of experts is poised to empower your drug development.

Elevate your research with our research stage production of monoclonal antibodies, bispecific antibodies, and antibody fragments (Fab, VHH, scFv).

Different Services for Different Stages of Antibody Discovery

We combined biologics drug development expertise with high-titer, high-purity antibody and protein production for research use.

Featured Services for Antibody Drug Development

At WuXi Biologics, our Protein Sciences (PS) Department provides research-grade antibody production services that harness the latest advancements in biotechnology. Whether you need monoclonal or bispecific antibodies, or antibody fragments (e.g., Fab, VHH, and scFv), we ensure every client receives top-quality proteins to drive groundbreaking research and therapeutic advancements.

 

A cost-effective, ultra-HTP antibody production platform that uses 96- and 24-well DWP format, resulting in a daily throughput of 1000x antibody production at 100 μg-1,500 μg per antibody, suitable for in vitro assays.

Learn More
 

An antibody production service that can provide antibodies that are low on endotoxin (<0.5 EU/mg) and aggregates (>95% monomer) at the scale of 1-100 mg, suitable for both in vitro and in vivo studies.

Learn More
 

A HTP bsAb production platform designed to unlock the optimal pairing of bsAb, with the ability to produce 1-7 mg customized bsAb with 99% heterodimer from 20 mL culture in a fast and cost-effective way (~3-4 weeks).

Learn More
 

A one-stop solution for early-stage antibody drug developability assessment using <1 mg protein.

Learn More
 

High-quality bsAbs, ranging from milligrams to grams, in just 4-6 weeks.

Learn More
 

Premium-quality monoclonal antibodies ranging from 1-100 grams in 3-4 weeks. Our platform synergizes ultra-high titer transient expression with flexible purification processes

Learn More
 

High-titer CHO production of soluble TCR proteins, TCR fusion proteins, and SCTs, as well as the refolded peptide-MHC complexes (RF-pMHC) production in E. coli.

Learn More
 

HTP high-titer CHO production of miniproteins with high yields and low endotoxin levels, surpassing traditional E. coli production methods.

Learn More

Case Study: High-Titer Expression of Antibody Drug Molecules Using the Ultra 96+ Platform

Our Ultra 96+ platform provides high-throughput (HTP) antibody production with a daily production of over a thousand antibodies. This advanced platform incorporates an ultra-high titer transient CHO expression system that significantly enhances titers and overall yields, as demonstrated below.

Figure A: The Ultra 96+ platform offers remarkable mean final yield of antibody drug molecules in in 1 mL culture using 96-DWP, achieving 1.2 mg for 960 antibodies, 0.98 mg for 536 VHH-Fc, 0.55 mg for 557 Fab, and 0.3 mg for 100 His-VHH. The proteins are suitable for in vitro assays.

The Ultra 96+ platform offers remarkable mean final yield of antibody drug molecules in in 1 mL culture using 96-DWP, achieving 1.2 mg for 960 antibodies, 0.98 mg for 536 VHH-Fc, 0.55 mg for 557 Fab, and 0.3 mg for 100 His-VHH. The proteins are suitable for in vitro assays.

Your Project. Our Expertise.

Contact Us